An aggressive mediastinal EBV-associated large B cell lymphoma.

Autor: Kurz KS; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany., Noerenberg D; Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin, Berlin, Germany., Schaich M; Klinik für Hämatologie, Onkologie und Palliativmedizin, Rems-Murr-Klinikum Winnenden, Winnenden, Germany., Bethge W; Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Horn H; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany., Staiger AM; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany., Fend F; Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany., Damm F; Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin, Berlin, Germany., Ott G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.

Publikováno v: Histopathology [Histopathology] 2024 Jul; Vol. 85 (1), pp. 195-197. Date of Electronic Publication: 2024 Apr 02.

Beyond the code: the role of histone methylation in cancer resistance and therapy.

Autor: Noerenberg D; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany., Damm F; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany. frederik.damm@charite.de.; German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK), Partner Site, Berlin, Germany. frederik.damm@charite.de.

Publikováno v: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Jun 12; Vol. 9 (1), pp. 161. Date of Electronic Publication: 2024 Jun 12.

Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.

Autor: Noerenberg D; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Briest F; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Hennch C; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Yoshida K; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Division of Cancer Evolution, National Cancer Center Research Institute, Tokyo, Japan., Hablesreiter R; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Takeuchi Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Ueno H; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Staiger AM; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart, and University of Tuebingen, Stuttgart, Germany., Ziepert M; Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany., Asmar F; Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Locher BN; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Toth E; Department of Surgical and Molecular Pathology, National Tumour Biology Laboratory, National Institute of Oncology, Budapest, Hungary., Weber T; Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany., Amini RM; Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden., Klapper W; Department of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Bouzani M; Department of Hematology and Lymphoma, BMTU, Evaggelismos General Hospital, Athens, Greece., Poeschel V; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany., Rosenwald A; Institute of Pathology, University of Würzburg and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany., Held G; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg, Germany.; Department Internal Medicine I, Westpfalzklinikum Kaiserslautern, Kaiserslautern, Germany., Campo E; Centro de Investigacion Biomedica en Red en Oncologia (CIBERONC), Madrid, Spain.; Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Ishaque N; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Center of Digital Health, Berlin, Germany., Stamatopoulos K; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece., Kanellis G; Department of Hematopathology, Evangelismos General Hospital, Athens, Greece., Anagnostopoulos I; Institute of Pathology, University of Würzburg and Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany.; Department of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Bullinger L; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Goldschmidt N; Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Bödör C; HCEMM-SE Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary., Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden., Vassilakopoulos TP; Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany.; Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Ott G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany., Ogawa S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Department of Medicine, Centre for Haematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan., Damm F; Department of Hematology, Oncology and Cancer Immunology, Campus Virchow, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Feb 01; Vol. 42 (4), pp. 452-466. Date of Electronic Publication: 2023 Dec 06.

Transcriptional reprogramming by mutated IRF4 in lymphoma.

Autor: Schleussner N; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Cauchy P; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.; University Medical Center Freiburg, 79106, Freiburg, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Franke V; Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany., Giefing M; Institute of Human Genetics, Polish Academy of Sciences, Poznan, 60-479, Poland.; Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany., Fornes O; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada., Vankadari N; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3000, Australia., Assi SA; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Costanza M; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Weniger MA; Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany., Akalin A; Bioinformatics and Omics Data Science Platform, Berlin Institute for Medical Systems Biology, Max-Delbrück-Center, Berlin, Germany., Anagnostopoulos I; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Bukur T; TRON gGmbH - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany., Casarotto MG; Research School of Biology, The Australian National University, Canberra, ACT, Australia., Damm F; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany., Daumke O; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany., Edginton-White B; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Gebhardt JCM; Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany., Grau M; Department of Physics, University of Marburg, 35052, Marburg, Germany.; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Grunwald S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Structural Biology, 13125, Berlin, Germany., Hansmann ML; Frankfurt Institute of Advanced Studies, Frankfurt am Main, Germany.; Institute for Pharmacology and Toxicology, Goethe University, Frankfurt am Main, Germany., Hartmann S; Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany., Huber L; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany., Kärgel E; Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Lusatis S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Noerenberg D; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany., Obier N; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Pannicke U; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany., Fischer A; Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany., Reisser A; Department of Physics, Institute of Biophysics, Ulm University, Ulm, Germany., Rosenwald A; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Schwarz K; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany.; Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Württemberg-Hessen, Ulm, Germany., Sundararaj S; Research School of Biology, The Australian National University, Canberra, ACT, Australia., Weilemann A; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Winkler W; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Xu W; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Lenz G; Medical Department A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Rajewsky K; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Immune Regulation and Cancer, 13125, Berlin, Germany., Wasserman WW; Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada., Cockerill PN; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Scheidereit C; Signal Transduction in Tumor Cells, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Siebert R; Institute of Human Genetics, Christian-Albrechts-University Kiel, 24105, Kiel, Germany.; Institute of Human Genetics, Ulm University and Ulm University Medical Center, 89081, Ulm, Germany., Küppers R; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122, Essen, Germany., Grosschedl R; Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany., Janz M; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Bonifer C; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK., Mathas S; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, 13125, Berlin, Germany. stephan.mathas@charite.de.; Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117, Berlin, Germany. stephan.mathas@charite.de.; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany. stephan.mathas@charite.de.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. stephan.mathas@charite.de.

Publikováno v: Nature communications [Nat Commun] 2023 Nov 07; Vol. 14 (1), pp. 6947. Date of Electronic Publication: 2023 Nov 07.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.